On the heels of its $900M Fund VI closing, Foresite Augments its Leadership Team with Two Partner Promotions

Foresite Capital, a multi-stage healthcare and life sciences investment firm with more than $3.5 billion in assets under management, today announced the promotion of Drs. Hyung Chun and Cindy Xiong to partner.

Foresite Capital recently announced the closing of a $900M fund that will continue the firm’s investing in groundbreaking technologies, ranging from novel therapeutics to companies at the intersection of technology and biotechnology. In their new roles, Xiong and Chun will lead investments across the Foresite portfolio focusing on a broad range of therapeutic areas, and continue to seek out new investment opportunities.

"Cindy and Hyung have demonstrated the ability to invest across both early and later stage opportunities working closely with entrepreneurs to build the next generation of healthcare companies,” said Jim Tananbaum, founder and CEO of Foresite Capital.

Michael Rome, managing director of Foresite Capital, added “They have both made a substantial impact across the Foresite portfolio leading to investments in novel areas, including next generation treatments for autoimmune diseases, innovative cellular therapies and medications for acute and chronic pain.”

Dr. Chun joined Foresite Capital in 2021 as a physician scientist from Yale School of Medicine, where he was a tenured professor and continues as an adjunct faculty member. He has published extensively in top journals including Nature, Science, New England Journal of Medicine, and is an inventor on multiple patents. He has served in multiple academic leadership roles including as Co-Director of the Yale Cardiovascular Research Center, and in advisory roles to multiple biotech companies. Chun completed his residency in internal medicine and fellowship in cardiovascular disease at Stanford University, holds an M.D. from Johns Hopkins School of Medicine and an A.B. in Biochemical Sciences from Harvard College. He serves on the boards of multiple Foresite portfolio companies including Latigo Therapeutics.

"It has been an amazing journey working with our outstanding investment team since joining Foresite nearly three years ago,” said Chun. “I am eager to continue our mission to address critical unmet needs in healthcare and make transformative impacts on patients’ lives."

Dr. Xiong joined Foresite Capital in 2019 as a member of the investment team, focusing on evaluating investment opportunities of private and public biotech companies. She serves on the boards of several portfolio companies including ImmPACT Bio and previously Xinthera Inc. (board observer, acquired by Gilead). Prior to Foresite, Xiong earned her MBA in Healthcare Management from the Wharton School. She received her PhD in Biology from the University of Michigan, where she studied neural regeneration, and was a Helen Hay Whitney postdoctoral fellow at UCSF, developing new technologies for genome and cell engineering. Xiong was the first scientist at Agenovir, where she led a team to develop CRISPR based therapeutics for HPV induced cancers.

“Since joining Foresite, I have had the privilege to work with an incredibly talented team that has supported my growth and career trajectory over the last five years,” said Xiong. “I am particularly excited about my next chapter at Foresite and look forward to partnering with visionary biotech companies that develop innovative therapies for large unmet medical needs.”

About Foresite Capital

Foresite Capital is a multi-stage healthcare and life sciences investment firm with more than $3.5 billion in assets under management. The firm aims to address areas of unmet medical need by funding promising healthcare and life sciences businesses at all stages of their life cycles. Founded in 2011, Foresite Capital is based in the San Francisco Bay Area, Los Angeles, and New York City. For more information, please visit www.foresitecapital.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240626109871/en/